Corvus Pharmaceuticals Files 8-K on Financials
Ticker: CRVS · Form: 8-K · Filed: Mar 25, 2025 · CIK: 1626971
| Field | Detail |
|---|---|
| Company | Corvus Pharmaceuticals, Inc. (CRVS) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Corvus Pharma dropped its 8-K on financials today.
AI Summary
Corvus Pharmaceuticals, Inc. filed an 8-K on March 25, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located in South San Francisco, California.
Why It Matters
This filing provides investors with an update on Corvus Pharmaceuticals' financial health and operational results, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Corvus Pharmaceuticals, Inc. (company) — Registrant
- March 25, 2025 (date) — Date of earliest event reported
- South San Francisco, CA (location) — Address of principal executive offices
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filed?
The filing was made on March 25, 2025.
What is the principal executive office location for Corvus Pharmaceuticals?
The principal executive offices are located at 901 Gateway Boulevard, Third Floor, South San Francisco, CA 94080.
What is the state of incorporation for Corvus Pharmaceuticals?
Corvus Pharmaceuticals, Inc. is incorporated in Delaware.
What is the IRS Employer Identification Number for Corvus Pharmaceuticals?
The IRS Employer Identification Number is 46-4670809.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 25, 2025 regarding Corvus Pharmaceuticals, Inc. (CRVS).